Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Risk of Suicidality in Depression with Serotonergic Antidepressants

Risk of Suicidality in Depression with Serotonergic Antidepressants Since depression is a risk factor for suicidal thoughts and behaviors, and since suicidal behaviors are associated with low serotonin activity, are selective serotonin reuptake inhibitors (SSRIs) more effective than other antidepressants in treating suicidality in depressed patients? There is inconclusive evidence for and against this hypothesis. However, all studies suggest that antidepressants are effective treatments of suicidal ideations and behaviors, and SSRIs have been shown to have prophylactic effects in preventing suicidal behaviors. Although some reports suggest that SSRIs might increase suicidal ideations and behaviors, the results of large, double-blind studies do not suggest a causal relationship between pharmacotherapy and the emergence of suicidality. Undertreatment of depression and therapeutic failure are more significant problems with the use of antidepressants in suicidal patients than the risk of using antidepressants in overdose. Prescribing inadequate doses of antidepressants is therefore a source of overlooked risk. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Risk of Suicidality in Depression with Serotonergic Antidepressants

Matthews, John; Fava, Maurizio
Annals of Clinical Psychiatry , Volume 12 (1) – Sep 30, 2004
Download PDF
8 pages

Loading next page...
 
/lp/springer-journals/risk-of-suicidality-in-depression-with-serotonergic-antidepressants-TzhBwRAGha
Publisher
Springer Journals
Copyright
Copyright © 2000 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1009027010991
Publisher site
See Article on Publisher Site

Abstract

Since depression is a risk factor for suicidal thoughts and behaviors, and since suicidal behaviors are associated with low serotonin activity, are selective serotonin reuptake inhibitors (SSRIs) more effective than other antidepressants in treating suicidality in depressed patients? There is inconclusive evidence for and against this hypothesis. However, all studies suggest that antidepressants are effective treatments of suicidal ideations and behaviors, and SSRIs have been shown to have prophylactic effects in preventing suicidal behaviors. Although some reports suggest that SSRIs might increase suicidal ideations and behaviors, the results of large, double-blind studies do not suggest a causal relationship between pharmacotherapy and the emergence of suicidality. Undertreatment of depression and therapeutic failure are more significant problems with the use of antidepressants in suicidal patients than the risk of using antidepressants in overdose. Prescribing inadequate doses of antidepressants is therefore a source of overlooked risk.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Sep 30, 2004

References

  • Suicide over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients
    Black, DW; Winokur, G
  • Depression and Mania
    Roose, SP; Glassman, AH
  • Risk of suicide in depression and its implication for psychopharmacological treatment
    Kasper, S; Schindler, S; Neumeister, A
  • Reduction of the Suicide Rate in Young People: Progress Review
    Regier, DA; Moscicki, EK
  • Risk factors for suicide in psychiatric patients
    Roy, A
  • The economic burden of depression
    Stoudemire, A; Frank, R; Hedemark, N; Kamlet, M; Blazer, D
  • Epidemiology and relative toxicity of antidepressant drugs
    Henry, JA
  • Suicide mortality among patients treated for depression in an insured population
    Simon, GE; VonKorff, M
  • “Serotonin depression”—A biochemical subgroup within the affective disorder
    Åsberg, M; Thoren, P; Traskman, L; Bertillsson, L; Ringberger, V
  • Cerebrospinal fluid amines and higher lethality suicide attempts in depressed inpatient
    Mann, JJ; Malone, KM
  • Suicide over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients
    Winchel, RM; Stanley, B; Stanley, M
  • 5–Hydroxytryptamine in the hind-brain of depressive suicides
    Shaw, DM; Camps, FE; Eccleston, EG
  • Determination of monoamine and monoamine metabolites in the human brain: Post mortem studies in a group of suicides and a control group
    Beskow, J; Gottfries, CG; Roos, BE; Winblad, B
  • Noradrenaline, 5–hydroxytryptamine, and 5–hydroxindoleacetic acid in the hindbrains of suicidal patients
    Bourne, HR; Bunney, WE; Colburn, RW; Davis, JM; Davis, JN; Shaw, DM; Coppen, AJ
  • 5–Hydroxytryptamine, noradrenaline, and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning
    Pare, CMB; Yeung, DP; Price, K; Stacey, RS
  • Serotonin and 5–hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients
    Lloyd, KG; Farley, IJ; Deck, JHN; Hornykiewicz, O
  • Tritiated imipramine binding sites are decreased in the frontal cortex of suicides
    Stanley, M; Virgilio, J; Gershon, S
  • Neurobiology of Mood Disorders
    Paul, SM; Rehavi, M; Skolnick, P; Goodwin, FK
  • Decreased imipramine binding in the brains of patients with depressive illness
    Perry, EK; Marshall, EF; Blessed, G; Tomlinson, BE; Perry, RH
  • Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimertype dementia and depression and suicides
    Crow, TJ; Cross, AJ; Cooper, SJ; Deakin, JFW; Ferrier, IN; Johnson, JA; Joseph, MH; Owen, F; Poulter, M; Lofthouse, R; Corsellis, JAN; Chambers, DR; Blessed, G; Perry, EK; Perry, RH; Tomlinson, BE
  • Human brain receptor alterations in suicide Victims
    Meyerson, LR; Wennogle, LP; Abel, MS; Coupet, J; Lippa, AS; Rauh, CE; Beer, B
  • Increased serotonin-2 binding sites in frontal cortex of suicide victims
    Stanley, M; Mann, JJ
  • Increased serotonin-2 and beta-1–adrenergic receptor binding in the frontal cortices of suicide victims
    Mann, JJ; Stanley, M; McBride, PA; McEwen, BS
  • The Third Generation of Progress
    Meltzer, HY; Lowry, M
  • Brain 5–HT-2 receptors and suicide
    Owen, F; Cross, AJ; Crow, TJ; Deakin, JFW; Ferrier, IN; Lofthouse, R; Poulter
  • Patterns of improvement in depressive symptoms with fluoxetine treatment
    Worthington, J; Fava, M; Davidson, K; Alpert, J; Nierenberg, AA; Rosenbaum, JF
  • A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder
    Mullin, JM; Pandita-Gunawardena, VR; Whitehead, AM
  • Citaloprarn versus mianserin
    De Wilde, J; Mertens, C; Fredicson Overo, K; Hepfner Peterson, HE
  • A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients
    Muijen, M; Roy, D; Silverstone, T; Mehmet, A; Christie
  • Fluvoxamine and imipramine in the treatment of depressive patients: A double-blind controlled study
    Gonella, G; Baignoli, G; Ecari
  • Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo
    Montgomery, S
  • Serotonin-Related Psychiatric Syndromes: Clinical and Therapeutic Links
    Sacchetti, E; Vita, A; Guarneri, L; Cornarcchia
  • Fluoxetine and suicide: Meta-analysis of controlled trials of treatment for depression
    Beasley, CM; Dornself, BE; Bosomworth, JC; Sayler, ME; Rampey, AH; Helligensteirl, JI; Thompson, VL; Murphy, DJ; Masica, DN
  • Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders
    Tollefson, GD; Fawectt, J; Winokur, G; Beasley, CM; Potvin, JH; Faries, DE; Rampey, AH; Sayler, ME
  • Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine
    Moller, HJ; Steinmeyer, EM
  • The role of neuropharmacologic selectivity in antidepressant action: Fluvoxamine versus desipramine
    Nathan, RS; Perel, JM; Pollock, BG; Kupfer, DJ
  • Adouble-blind, randomized comparison of fluvoxamine with mianserin in depressive illness
    Perez, A; Ashford, JJ
  • Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression
    Verkes, RJ; Van der Mast, RC; Heingeveld, MW; Tuyl, JP; Zwinderman, AH; Van Kempen, GM
  • Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial
    Thies-Flechtner, K; Muller-Oerlinghausen, B; Seibert, W; Walther, A; Greil, W
  • The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy
    Mann, JJ; Kapur, S
  • Assessment of suicidal intention: The scale for suicidal ideation
    Beck, AT; Kovacs, M; Weissman, A
  • The utilization of antidepressants—A key issue in the prevention of suicide: An analysis of 5281 suicides in Sweden during the period 1992-1994
    Isacsson, G; Holmgren, P; Druid, H; Bergman, U
  • Antidepressants and suicide risk: Issues of chemical and behavioral toxicity
    Molcho, A; Stanley, M
  • Moderm Psychiatric Treatment
    Detre, TP; Jarecki, HG
  • Paradoxical worsening of depressive symptomatology caused by antidepressants
    Damluji, NF; Ferguson, JM
  • Paradoxical effects of amitriptyline on borderline patients
    Soloff, PH; George, A; Nathan, RS; Schulz, PM; Perel, JM
  • Alprazolam-induced dyscontrol in borderline personality disorder
    Gardner, D; Cowdry, R
  • Emergence of intense suicidal preoccupation during fluoxetine treatment
    Teicher, MH; Glod, C; Cole, JO
  • Suicidality and fluoxetine: Is there a relationship
    Fava, M; Rosenbaum, JF
  • 5–HT reuptake inhibitors, tricyclic antidepressants, and suicidal Behavior
    Baldwin, D; Bullock, T; Montgomery, D; Montgomery, S
  • Prophylactic potential of selective reuptake inhibitors in suicidal patients
    Banki, CM
  • Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression
    Tollefson, GD; Rampey, AH; Beasley, CM; Enas, GG; Potvin, JH
  • Antidepressants, depression and suicide: An analysis of the San Diego study
    Isacsson, G; Bergman, U; Rich, CL
  • Self-poisonings with antidepressants and other psychotropics in an urban area of Sweden
    Isacsson, G; Wasserman, D; Bergman, U
  • Risk of suicide attempts after benzodiazepine and/or antidepressant use
    Neutel, C.; Patten, SB
  • Suicide and mental disorder in Swedish men
    Beskow, J
  • Suicide in psychiatric patients
    Myers, DH; Neal, CD
  • Treatment-emergent side effects of the newer antidepressants
    Fava, M; Rosenbaum, JF
  • Relative mortality from overdose of antidepressants
    Henry, JA; Alexander, CA; Sener, EK
  • Suicide and the cost-effectiveness of antidepressants
    Henry, JA
  • Antidepressant overdoses and resultant emergency department services: The impact of SSRIs
    Stoner, SC; Marken, PA; Watson, WA; Switzer, JL; Barber, MF; Meyer, VL; Sommi, RW; Steele, MT